EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹412 Cr
Expense Ratio
0.79%
ISIN
INF174KA1PZ7
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.32%
+17.55% (Cat Avg.)
Since Inception
+22.13%
— (Cat Avg.)
Equity | ₹404.41 Cr | 98.27% |
Others | ₹7.13 Cr | 1.73% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹73.72 Cr | 17.91% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹33.46 Cr | 8.13% |
Cipla Ltd | Equity | ₹24.81 Cr | 6.03% |
Divi's Laboratories Ltd | Equity | ₹20.79 Cr | 5.05% |
Torrent Pharmaceuticals Ltd | Equity | ₹15.82 Cr | 3.84% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹15.42 Cr | 3.75% |
Lupin Ltd | Equity | ₹14.6 Cr | 3.55% |
Dr Reddy's Laboratories Ltd | Equity | ₹14.3 Cr | 3.48% |
Aurobindo Pharma Ltd | Equity | ₹14.04 Cr | 3.41% |
Apollo Hospitals Enterprise Ltd | Equity | ₹13.23 Cr | 3.22% |
Jubilant Pharmova Ltd | Equity | ₹12.54 Cr | 3.05% |
Alkem Laboratories Ltd | Equity | ₹11.72 Cr | 2.85% |
Sai Life Sciences Ltd | Equity | ₹11.41 Cr | 2.77% |
Ami Organics Ltd | Equity | ₹10.98 Cr | 2.67% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹10.4 Cr | 2.53% |
Ajanta Pharma Ltd | Equity | ₹10.33 Cr | 2.51% |
Zydus Lifesciences Ltd | Equity | ₹10.19 Cr | 2.48% |
Mankind Pharma Ltd | Equity | ₹9.7 Cr | 2.36% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹9.59 Cr | 2.33% |
Laxmi Dental Ltd | Equity | ₹9.06 Cr | 2.20% |
Glenmark Pharmaceuticals Ltd | Equity | ₹8.78 Cr | 2.13% |
Hikal Ltd | Equity | ₹8.39 Cr | 2.04% |
Fortis Healthcare Ltd | Equity | ₹8.38 Cr | 2.04% |
Krsnaa Diagnostics Ltd | Equity | ₹7.88 Cr | 1.91% |
Triparty Repo | Cash - Repurchase Agreement | ₹7.8 Cr | 1.89% |
Orchid Pharma Ltd | Equity | ₹7.76 Cr | 1.89% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹7.14 Cr | 1.73% |
Marksans Pharma Ltd | Equity | ₹5.56 Cr | 1.35% |
Innova Captab Ltd | Equity | ₹4.39 Cr | 1.07% |
Net Current Assets/(Liabilities) | Cash | ₹-0.67 Cr | 0.16% |
Large Cap Stocks
38.79%
Mid Cap Stocks
30.19%
Small Cap Stocks
27.09%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹393.43 Cr | 95.60% |
Basic Materials | ₹10.98 Cr | 2.67% |
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since December 2023
Since December 2023
Since March 2024
ISIN INF174KA1PZ7 | Expense Ratio 0.79% | Exit Load No Charges | Fund Size ₹412 Cr | Age 1 year 4 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹4,85,992 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹412 Cr
Expense Ratio
0.79%
ISIN
INF174KA1PZ7
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.32%
+17.55% (Cat Avg.)
Since Inception
+22.13%
— (Cat Avg.)
Equity | ₹404.41 Cr | 98.27% |
Others | ₹7.13 Cr | 1.73% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹73.72 Cr | 17.91% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹33.46 Cr | 8.13% |
Cipla Ltd | Equity | ₹24.81 Cr | 6.03% |
Divi's Laboratories Ltd | Equity | ₹20.79 Cr | 5.05% |
Torrent Pharmaceuticals Ltd | Equity | ₹15.82 Cr | 3.84% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹15.42 Cr | 3.75% |
Lupin Ltd | Equity | ₹14.6 Cr | 3.55% |
Dr Reddy's Laboratories Ltd | Equity | ₹14.3 Cr | 3.48% |
Aurobindo Pharma Ltd | Equity | ₹14.04 Cr | 3.41% |
Apollo Hospitals Enterprise Ltd | Equity | ₹13.23 Cr | 3.22% |
Jubilant Pharmova Ltd | Equity | ₹12.54 Cr | 3.05% |
Alkem Laboratories Ltd | Equity | ₹11.72 Cr | 2.85% |
Sai Life Sciences Ltd | Equity | ₹11.41 Cr | 2.77% |
Ami Organics Ltd | Equity | ₹10.98 Cr | 2.67% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹10.4 Cr | 2.53% |
Ajanta Pharma Ltd | Equity | ₹10.33 Cr | 2.51% |
Zydus Lifesciences Ltd | Equity | ₹10.19 Cr | 2.48% |
Mankind Pharma Ltd | Equity | ₹9.7 Cr | 2.36% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹9.59 Cr | 2.33% |
Laxmi Dental Ltd | Equity | ₹9.06 Cr | 2.20% |
Glenmark Pharmaceuticals Ltd | Equity | ₹8.78 Cr | 2.13% |
Hikal Ltd | Equity | ₹8.39 Cr | 2.04% |
Fortis Healthcare Ltd | Equity | ₹8.38 Cr | 2.04% |
Krsnaa Diagnostics Ltd | Equity | ₹7.88 Cr | 1.91% |
Triparty Repo | Cash - Repurchase Agreement | ₹7.8 Cr | 1.89% |
Orchid Pharma Ltd | Equity | ₹7.76 Cr | 1.89% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹7.14 Cr | 1.73% |
Marksans Pharma Ltd | Equity | ₹5.56 Cr | 1.35% |
Innova Captab Ltd | Equity | ₹4.39 Cr | 1.07% |
Net Current Assets/(Liabilities) | Cash | ₹-0.67 Cr | 0.16% |
Large Cap Stocks
38.79%
Mid Cap Stocks
30.19%
Small Cap Stocks
27.09%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹393.43 Cr | 95.60% |
Basic Materials | ₹10.98 Cr | 2.67% |
Standard Deviation
This fund
--
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since December 2023
Since December 2023
Since March 2024
ISIN INF174KA1PZ7 | Expense Ratio 0.79% | Exit Load No Charges | Fund Size ₹412 Cr | Age 1 year 4 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹4,85,992 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments